IGFBP3 and metabolic dysfunction-associated steatotic liver disease: Finally, higher IGFBP3 levels in NAFLD patients may reduce the bioavailability of IGF1 in the liver tissue, including the overexpression of microRNA-190b (miR-190b) in patients with NAFLD which suppresses IGF1 expression and induces lipid accumulation and IR.